HAVCR2 and acute myeloid leukemia: CD3 + T cells from patients with newly diagnosed AML were sorted and treated with JQ1 or vehicle control (DMSO) for 24 hours, then PD-1 and Tim-3 levels were measured at the end of drug treatment by FCM (Fig. 4A and Supplemental Fig. 3A).